Cargando…

Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains

Human coronavirus 229E (HCoV-229E) infection in infants, elderly people, and immunocompromised patients can cause severe disease, thus calling for the development of effective and safe therapeutics to treat it. Here we reported the design, synthesis and characterization of two peptide-based membrane...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Shuai, Xu, Wei, Wang, Qian, Wang, Cong, Hua, Chen, Li, Weihua, Lu, Lu, Jiang, Shibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855709/ https://www.ncbi.nlm.nih.gov/pubmed/29415501 http://dx.doi.org/10.3390/ijms19020487

Ejemplares similares

Heparan Sulfate and Enoxaparin Interact at the Interface of the Spike Protein of HCoV-229E but Not with HCoV-OC43
por: Fuochi, Virginia, et al.
Publicado: (2023)

Structural characterization of the HCoV-229E fusion core
por: Zhang, Wei, et al.
Publicado: (2018)

Characterization of HCoV-229E fusion core: Implications for structure basis of coronavirus membrane fusion
por: Liu, Cheng, et al.
Publicado: (2006)

Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host
por: Forni, Diego, et al.
Publicado: (2021)

HCoV-229E Infects and Activates Monocytes
por: Desforges, Marc, et al.
Publicado: (2006)

Titration of Human Coronaviruses, HCoV-229E and HCoV-OC43, by an Indirect Immunoperoxidase Assay
por: Lambert, Francine, et al.
Publicado: (2007)

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
por: Xia, Shuai, et al.
Publicado: (2019)

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
por: Xia, Shuai, et al.
Publicado: (2020)

Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4
por: Xia, Shuai, et al.
Publicado: (2019)

Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study
por: Aldridge, Robert W., et al.
Publicado: (2020)

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2012)

Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2
por: Liu, Donglan, et al.
Publicado: (2023)

Cryo-EM analysis of the HCoV-229E spike glycoprotein reveals dynamic prefusion conformational changes
por: Song, Xiyong, et al.
Publicado: (2021)

The human coronavirus HCoV-229E S-protein structure and receptor binding
por: Li, Zhijie, et al.
Publicado: (2019)

Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein
por: Xiang, Jiangchao, et al.
Publicado: (2022)

Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332
por: Zhou, Yanru, et al.
Publicado: (2023)

Fatal human coronavirus 229E (HCoV-229E) and RSV–Related pneumonia in an AIDS patient from Colombia
por: Villamil-Gómez, Wilmer E., et al.
Publicado: (2020)

Pan-Coronavirus CRISPR-CasRx Effector System Significantly Reduces Viable Titer in HCoV-OC43, HCoV-229E, and SARS-CoV-2
por: Mayes, Cathryn M., et al.
Publicado: (2023)

Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs against Human Coronavirus 229E (HCoV-229E)
por: Parang, Keykavous, et al.
Publicado: (2020)

A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC
por: Jiang, Shibo, et al.
Publicado: (2013)

Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro
por: Pasquereau, Sébastien, et al.
Publicado: (2021)

Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD
por: Wang, Cong, et al.
Publicado: (2019)

Coronavirus humains (HCoV)
por: Vabret, A., et al.
Publicado: (2009)

The therapeutic promises of Lianhuaqingke in the mice model of coronavirus pneumonia (HCoV-229E and SARS-CoV-2)
por: Wang, Mingye, et al.
Publicado: (2021)

Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors
por: Liu, I-Jung, et al.
Publicado: (2009)

Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells
por: Friedman, Nehemya, et al.
Publicado: (2021)

Dimerized fusion inhibitor peptides targeting the HR1–HR2 interaction of SARS-CoV-2
por: Tsuji, Kohei, et al.
Publicado: (2023)

Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry
por: Sun, Huan, et al.
Publicado: (2020)

Antiviral Activity of Ficus rubiginosa Leaf Extracts against HSV-1, HCoV-229E and PV-1
por: Dell’Annunziata, Federica, et al.
Publicado: (2022)

Ferulic acid derivatives block coronaviruses HCoV-229E and SARS-CoV-2 replication in vitro
por: Pasquereau, Sébastien, et al.
Publicado: (2022)

Corrigendum to ’Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506’ Virus Research (2012) 165/1 [112-117]: Corrigendum
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2022)

Novel polymeric inhibitors of HCoV-NL63
por: Milewska, Aleksandra, et al.
Publicado: (2013)

Human Coronaviruses HCoV-NL63 and HCoV-HKU1 in Hospitalized Children with Acute Respiratory Infections in Beijing, China
por: Cui, Li-Jin, et al.
Publicado: (2011)

Liposomal Lactoferrin Exerts Antiviral Activity against HCoV-229E and SARS-CoV-2 Pseudoviruses In Vitro
por: Andreu, Sabina, et al.
Publicado: (2023)

Effect of Jinzhen granule on two coronaviruses: The novel SARS-CoV-2 and the HCoV-229E and the evidences for their mechanisms of action
por: Ma, Qinhai, et al.
Publicado: (2022)

Previous viral symptoms and individual mothers influenced the leveled duration of human milk antibodies cross-reactive to S1 and S2 subunits from SARS-CoV-2, HCoV-229E, and HCoV-OC43
por: Demers-Mathieu, Veronique, et al.
Publicado: (2021)

Human Milk Antibodies against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with a Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers
por: Demers-Mathieu, Veronique, et al.
Publicado: (2021)

Surveillance of endemic human coronaviruses (HCoV-NL63, OC43 and 229E) associated with childhood pneumonia in Kilifi, Kenya
por: Otieno, Grieven P., et al.
Publicado: (2020)

Nebulized CLODOS Technology Shows Clear Virucidal Properties against the Human Coronavirus HCoV-229E at Non-Cytotoxic Doses
por: Andreu, Sabina, et al.
Publicado: (2021)

Assessment of Antiviral Coatings for High-Touch Surfaces by Using Human Coronaviruses HCoV-229E and SARS-CoV-2
por: Butot, S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jrgtike6sjju95edo8feqs842u